22:21:39 EDT Tue 23 Apr 2024
Enter Symbol
or Name

Login ID:
Innocan Pharma Corp
Symbol INNO
Shares Issued 248,490,093
Close 2023-03-31 C$ 0.235
Market Cap C$ 58,395,172
Recent Sedar Documents

Innocan Pharma applies for cannabinoid platform patent

2023-04-03 13:25 ET - News Release

Ms. Iris Bincovich reports


Innocan Pharma Corp. has filed a joint application with Ramot at Tel Aviv University Ltd. to the World Intellectual Property Organization. The application pertains to the development of a novel platform for loading cannabinoids on exosomes.

The collaboration between Innocan and Ramot (Tel Aviv University's technology transfer company) is aimed at creating a drug delivery platform that maximizes the activity of loaded cannabinoids. The new international patent application resulting from this joint effort is expected to expand the intellectual property space for cannabis-based products, opening exciting breakthrough opportunities.

"Ramot is excited about the fruitful collaboration with Innocan and believes that the new drug delivery platform that maximizes the activity of charged cannabinoids will lead to new breakthroughs in the field of drug delivery platforms," said Keren Primor Cohen, Ramot's chief executive officer.

Commenting on this development, Iris Bincovich, CEO of Innocan Pharma, said: "We are delighted to announce this joint application with Ramot at Tel Aviv University. This is an important milestone for us, and it reflects the strength of our collaboration and the potential of our partnership. We are committed to bringing innovative solutions to patients and look forward to the outcomes of this exciting project."

Innocan's portfolio of targeted healing products continues to expand, positioning the company as a leader in the field of cannabis-based therapeutics. With this new application, the company is well positioned to unlock even greater potential for patients in need of effective treatment for chronic conditions.

About Innocan Pharma Corp.

Innocan is a pharmaceutical tech company that operates under two main segments: pharmaceuticals and consumer wellness. In the pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprising cannabinoids science to treat various conditions to improve patients' quality of life. This segment involves two drug delivery technologies: (i) liposome platform technology (LPT) CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream; the LPT delivery platform research is in the preclinical trial phase for two indications: epilepsy and pain management; (ii) CLX CBD-loaded exosomes platform that may hold the potential to provide a highly synergistic effect of regenerating and anti-inflammatory properties targeting the central nervous system (CNS). In the consumer wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted on-line sales.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.